Niva Bupa Health Insurance Company Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Niva Bupa Health Insurance Company Ltd trades at ₹86.1, in a confirmed uptrend and 8 weeks into that stage. That is +7.7% against its own 200-day average. It sits at 95% of a 52-week range of ₹70 to ₹87. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week.

Today the stock is in a confirmed uptrend — week 8 of stage 2, confirmed. At ₹86.1 it trades +7.7% versus its 200-day average and sits at 95% of its 52-week range (₹70–₹87).

Against the market, two honest reads. Cumulative: over the last 1.7 years the stock moved +16% while the NIFTY 500 moved +6% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/BV sits at the 83rd percentile of its own range.

Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each ₹1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.

Niva Bupa Health Insurance Company Ltd trades at 4.2× P/BV, at the pricey end of its own range (83rd percentile). Its long-run median P/BV is 4.0×, measured across 1.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/BV of 4.2× is at the pricey end of its own range (83rd percentile), against a long-run median of 4.0× measured over 1.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

The honest context for that discount: a bank earning about 3% on its equity is worth less per rupee of book, and the market has priced that in rather than overlooked it. The discount closes only if the returns themselves improve.

🚨 Why the multiple sits where it does: over the past year book value grew while the price moved −3.6% — the price ran ahead of the book, pushing the multiple up its own range.

Put together: the multiple is full against its own past, so the story rests on the book-value line underneath it, not the multiple.

The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 860% on reported income across 11 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Niva Bupa Health Insurance Company Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 7 quarters across 0 curves, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

54.0/100 — rank 2 of 8 in Finance - Insurance · 67% evidence confidence

Niva Bupa Health Insurance Company Ltd scores 54.0 out of 100 against the 8 companies it is compared with in Finance - Insurance, ranking 2. Price leads the evidence: RS versus the benchmark is 7.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation.

The four contributions add to the total exactly: 17.1 + 13.1 + 3.8 + 20 = 54. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.

Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fee and other income.

Niva Bupa Health Insurance Company Ltd reported ₹2,139 Cr of income in the Mar 26 quarter, +28.0% year on year. That is the 7th straight quarter of year-on-year growth. Over 7 years it has compounded at 34.3% a year. The last full year, FY26, came in at ₹6,695 Cr. The last four reported quarters add to ₹6,695 Cr.

Niva Bupa Health Insurance Company Ltd reported ₹2,139 Cr of income in the Mar 26 quarter, +28.0% year on year. That is the 7th straight quarter of year-on-year growth. Over 7 years it has compounded at 34.3% a year. The last full year, FY26, came in at ₹6,695 Cr. The last four reported quarters add to ₹6,695 Cr.

FY26 revenue came in at ₹6,695 Cr (+24.6% on the year), capping 7 years at 34.3% compound. The latest quarter (Mar 26) printed ₹2,139 Cr, +28.0% year on year — the 7th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +24.3% growth against the decade's 34.3% — the current year is running slower than its own long-run rate.

→ Revenue grew — did the net margin hold as it scaled? Next: 16.1% this quarter (+3.8 pp YoY).

Net margin Net margin — what the bank keeps of every ₹100 of revenue after every cost, provision and tax. It is the cleanest single margin we can read for a lender.

Niva Bupa Health Insurance Company Ltd's net margin is 16.1% in the Mar 26 quarter, +3.8 percentage points against the same quarter a year ago. Across 8 fiscal years the net margin has ranged −10.5% to 4.0%. The current quarter is running above every full year in that window.

Niva Bupa Health Insurance Company Ltd's net margin is 16.1% in the Mar 26 quarter, +3.8 percentage points against the same quarter a year ago. Across 8 fiscal years the net margin has ranged −10.5% to 4.0%. The current quarter is running above every full year in that window.

The latest quarter's net margin is 16.1%, +3.8 pp against the same quarter a year ago. Across 8 fiscal years the net margin has ranged −10.5%–4.0%.

Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.

→ The net margin held — did that reach the bottom line? Next: profit +67.5% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Niva Bupa Health Insurance Company Ltd earned ₹345 Cr of net profit in the Mar 26 quarter, +67.5% year on year. Full-year FY26 profit was ₹131 Cr. That is 16.1% of the quarter's revenue. The same quarter a year earlier earned ₹206 Cr. 5 of the last 11 reported quarters were loss-making.

Niva Bupa Health Insurance Company Ltd earned ₹345 Cr of net profit in the Mar 26 quarter, +67.5% year on year. Full-year FY26 profit was ₹131 Cr. That is 16.1% of the quarter's revenue. The same quarter a year earlier earned ₹206 Cr. 5 of the last 11 reported quarters were loss-making.

Mar 26 profit was ₹345 Cr, +67.5% year on year. On the full year, FY26 printed ₹131 Cr (−38.8%).

Why profit moved: revenue contributed +28.0% and the margin +3.8 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit −359.5% vs revenue +24.3%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

→ Profit is up — how clean is the loan book behind it? Next: we hold no quarterly loan-book numbers — the section says so plainly.

Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.

Loan-book quality history is not available for Niva Bupa Health Insurance Company Ltd, so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line.

We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.

Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.

→ Behind the profits — is the book itself still growing? Next: revenue grew +24.6% in FY26.

The loan book We read the loan book through revenue — when the book grows, revenue grows with it. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.

Niva Bupa Health Insurance Company Ltd's revenue grew +24.6% in FY26 to ₹6,695 Cr, so the book is growing. The latest quarter ran +28.0% year on year. The net margin on that income is 16.1%, +3.8 percentage points against a year ago.

FY26 revenue was ₹6,695 Cr, +24.6% on the year, and the latest quarter ran +28.0% year on year. The net margin on that revenue is 16.1% this quarter (+3.8 pp YoY) — growth with a widening margin on it.

The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — gross NPA is the loan-quality read we carry here.

→ Does all of this actually earn its keep on equity? Next: ROE is 3%.

Returns on equity and assets Two numbers usually rate a lender: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys.

A clean annual return-on-equity ladder is not held for Niva Bupa Health Insurance Company Ltd. For an insurer especially the standard bank ratios are not the right lens, so this page does not force them onto the filings rather than estimating a series it cannot support.

We do not hold a clean annual return-on-equity series for Niva Bupa Health Insurance Company Ltd — for an insurer especially, the standard bank ratios are not the right lens, so this page does not force them. The revenue, margin and ownership sections above and below are the reads we stand behind.

The quarterly return-on-equity and return-on-assets curves, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 860% on reported income across 11 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

→ Who owns Niva Bupa Health Insurance Company Ltd, and are they adding or leaving? Next: Domestic institutions added 6.4 points over 6 quarters.

Debt

For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.

A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.

→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 6.4 points over 6 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 6.4 points of Niva Bupa Health Insurance Company Ltd over 6 quarters, the biggest move on the register. That takes domestic institutions to 16.2% of the company. Foreign institutions moved +3.2 points over the same window, to 12.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +6.4 points over 6 quarters to 16.2%; Foreign institutions: +3.2 points over 6 quarters to 12.1%; Promoters: −0.7 points over 6 quarters to 55.3%.

Why the register moved: domestic institutions drove it (+6.4 points), alongside foreign institutions (+3.2 points) — steady accumulation by institutions reading the same numbers this page reads.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Niva Bupa Health Insurance Company Ltd: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.

The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.

Frequently asked questions